These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2040 related articles for article (PubMed ID: 26181256)

  • 41. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience.
    Lazaridis KN; Schahl KA; Cousin MA; Babovic-Vuksanovic D; Riegert-Johnson DL; Gavrilova RH; McAllister TM; Lindor NM; Abraham RS; Ackerman MJ; Pichurin PN; Deyle DR; Gavrilov DK; Hand JL; Klee EW; Stephens MC; Wick MJ; Atkinson EJ; Linden DR; Ferber MJ; Wieben ED; Farrugia G;
    Mayo Clin Proc; 2016 Mar; 91(3):297-307. PubMed ID: 26944241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genomic Profiling: Building a Continuum From Knowledge to Care.
    Chen HX; Abrams JS
    JAMA Oncol; 2015 Jul; 1(4):474-5. PubMed ID: 26181257
    [No Abstract]   [Full Text] [Related]  

  • 44. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
    Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
    Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene.
    Tada H; Kawashiri MA; Nohara A; Saito R; Tanaka Y; Nomura A; Konno T; Sakata K; Fujino N; Takamura T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Atherosclerosis; 2015 Jun; 240(2):324-9. PubMed ID: 25875382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned.
    Ghaoui R; Cooper ST; Lek M; Jones K; Corbett A; Reddel SW; Needham M; Liang C; Waddell LB; Nicholson G; O'Grady G; Kaur S; Ong R; Davis M; Sue CM; Laing NG; North KN; MacArthur DG; Clarke NF
    JAMA Neurol; 2015 Dec; 72(12):1424-32. PubMed ID: 26436962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
    Tran B; Brown AM; Bedard PL; Winquist E; Goss GD; Hotte SJ; Welch SA; Hirte HW; Zhang T; Stein LD; Ferretti V; Watt S; Jiao W; Ng K; Ghai S; Shaw P; Petrocelli T; Hudson TJ; Neel BG; Onetto N; Siu LL; McPherson JD; Kamel-Reid S; Dancey JE
    Int J Cancer; 2013 Apr; 132(7):1547-55. PubMed ID: 22948899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
    Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
    Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
    Trédan O; Wang Q; Pissaloux D; Cassier P; de la Fouchardière A; Fayette J; Desseigne F; Ray-Coquard I; de la Fouchardière C; Frappaz D; Heudel PE; Bonneville-Levard A; Fléchon A; Sarabi M; Guibert P; Bachelot T; Pérol M; You B; Bonnin N; Collard O; Leyronnas C; Attignon V; Baudet C; Sohier E; Villemin JP; Viari A; Boyault S; Lantuejoul S; Paindavoine S; Treillleux I; Rodriguez C; Agrapart V; Corset V; Garin G; Chabaud S; Pérol D; Blay JY;
    Ann Oncol; 2019 May; 30(5):757-765. PubMed ID: 30865223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.
    Peveling-Oberhag J; Wolters F; Döring C; Walter D; Sellmann L; Scholtysik R; Lucioni M; Schubach M; Paulli M; Biskup S; Zeuzem S; Küppers R; Hansmann ML
    BMC Cancer; 2015 Oct; 15():773. PubMed ID: 26498442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Computational analysis in cancer exome sequencing.
    Evans P; Kong Y; Krauthammer M
    Methods Mol Biol; 2014; 1176():219-27. PubMed ID: 25030931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
    Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
    Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma.
    Zhao P; Chen H; Wen D; Mou S; Zhang F; Zheng S
    Cancer Commun (Lond); 2018 Aug; 38(1):54. PubMed ID: 30139386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The emerging significance of secondary germline testing in cancer genomics.
    Mandelker D; Zhang L
    J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent exome-targeted next-generation sequencing and single nucleotide polymorphism array to identify the causative genetic aberrations of isolated Mayer-Rokitansky-Küster-Hauser syndrome.
    Chen MJ; Wei SY; Yang WS; Wu TT; Li HY; Ho HN; Yang YS; Chen PL
    Hum Reprod; 2015 Jul; 30(7):1732-42. PubMed ID: 25924657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
    Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
    BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 102.